

COVID-19 and Indian population: a comparative genetic analysis

Saurabh Patil¹, Sandhya Kiran Pemmasani^{1*}, Neelima Chitturi¹, Ishita Bhatnagar¹, Anuradha Acharya¹, Lingareddy Venkata Subash¹

¹ Research and Development Division, Mapmygenome India Limited, Hyderabad, India

* Correspondence:

Dr. Sandhya Kiran Pemmasani

drsandhyakiran@mapmygenome.in

Keywords: COVID-19, COVID-19 susceptibility, COVID-19 severity, comparative genetics, corona virus, SARS-CoV2

ABSTRACT

Background

Major risk factors of COVID-19 include older age, male gender, and comorbidities. In addition, host genetic makeup is also known to play a major role in COVID-19 susceptibility and severity. To assess the genetic predisposition of the Indian population to COVID-19, a comparative analysis of the frequencies of polymorphisms directly or potentially associated with COVID-19 susceptibility, severity, immune response, and fatal outcomes was done between the Indian population and other major populations (European, African, East Asian, South Asian, and American).

Materials and methods

Polymorphisms directly or potentially associated with COVID-19 susceptibility, severity, immune response, and mortality were mined from genetic association studies, comparative genetic studies, expression quantitative trait loci studies among others. Genotype data of these polymorphisms were either sourced from the GenomagaDBTM database of Mapmygenome India Ltd. (sample size = 3054; Indian origin) or were imputed. Polymorphisms with minor allele frequency ≥ 0.05 and that are in Hardy-Weinberg equilibrium in the Indian population were considered for allele frequency comparison between the Indian population and 1000 Genome population groups.

Results

Allele frequencies of 421 polymorphisms were found to be significantly different in the Indian population compared to European, African, East Asian, South Asian, and American populations. 128 polymorphisms were shortlisted based on linkage disequilibrium and were analyzed in detail. Apart from well-studied genes, like ACE2, TMPRSS2, ADAM17, and FURIN, variants from AHSB, IFITM3, PTPN2, CD209, CCL5, HEATR9, SELENBP9, AGO1, HLA-G, MX1, ICAM3, MUC5B, CRP, C1GALT1, and other genes were also found to be significantly different in Indian population. These variants might be implicated in COVID-19 susceptibility and progression.

Conclusion

Our comparative study unraveled multiple genetic variants whose allele frequencies were significantly different in the Indian population and might have a potential role in COVID-19 susceptibility, its severity, and fatal outcomes. This study can be very useful for selecting candidate genes/variants for future COVID-19 related genetic association studies.

1 INTRODUCTION

Coronavirus disease - 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), has strained the healthcare system and economy of a majority of nations and has crippled the human population [1, 2, 3]. COVID-19 is characterized by a range of clinical features which are categorized as most common, less common, and rare (severe). The most common symptoms are fever, dry cough, and fatigue, while less common symptoms are pneumonia without noticeable hypoxemia, sputum production, sore throat, headache, chest pain, and diarrhea [4, 5]. Acute respiratory distress syndrome, sepsis, acute cardiac injury, heart failure, acute kidney injury, hypoxic encephalopathy are more common in severe cases [4, 5, 6]. Severe patients show elevated levels of pro-inflammatory cytokines, indicating the presence of cytokine storm [4]. Self-reported loss of smell and taste was also observed in some cases [7].

Major risk factors for COVID-19 severity are older age, male gender, and comorbidities. A higher case fatality rate (CFR) has been observed in older adults as compared to the younger population [8, 9, 10, 11, 12]. Relatively fewer female deaths are consistently observed as compared to males [10, 11, 12]. COVID-19 patients with comorbidities like hypertension, obesity, diabetes, and others are more likely to develop severe complications than ones without any underlying diseases [13, 14, 15, 16, 17, 18]. ABO blood groups also seem to be contributing to COVID-19 related risk. While blood group A is associated with an increased risk of severe COVID-19 outcomes, blood group O seems to be protective [19, 20, 21].

In addition to the above risk factors, host genetics can modulate susceptibility and severity of the disease by regulating viral entry and host immune response [22, 23]. For example, rs12329760 (p.Val197Met) affects the stability of TMPRSS2 protein, which is implicated in SARS-CoV2 viral entry into host cells. This polymorphism was found to be less frequent in severe COVID-19 cases as compared to others, suggesting its protective role against severe outcomes of COVID-19 [24]. The C allele of rs12252 in the IFITM3 gene that is known for inhibiting influenza virus entry into host cells was found to be a genetic risk factor for COVID-19 hospitalization and severe outcomes [25, 26]. 3p21.31 gene cluster confers genetic susceptibility to COVID-19 with respiratory failure in Italian and Spanish populations [27]. Genetic variants present in immune-related genes like HLA [24, 28, 29, 30], IL-6 [24], TNF-alpha [31], C5 [32, 33] are associated with COVID-19 severity.

While the majority of these studies were done on European and East Asian populations, limited studies were done on the Indian population [34, 35, 36]. Considering the significant role of host genetics in COVID-19 susceptibility and severity in the Indian population, we analyzed the frequencies of the polymorphisms that are directly or indirectly implicated in COVID-19. We have also made a comparison between Indian and other populations to understand allele frequency distribution globally.

2 MATERIALS AND METHODS

2.1 Literature mining and polymorphism selection:

Research articles related to COVID-19 genetic associations were searched in Pubmed using keywords such as 'COVID', 'COVID-19', 'Corona virus', 'GWAS', 'genetic susceptibility', 'polymorphism', 'severity', 'susceptibility' among other relevant terms. A total of 1418 research

articles were found, which were thoroughly screened and 99 relevant articles were selected. A total of 1974 polymorphisms were shortlisted from the selected articles.

2.2 Genotype data for Indian population:

The GenomeDBTM database of Mapmygenome India Ltd. [153] was accessed to obtain genotype data for the present study. It is a human polymorphism genotype database developed and owned by Mapmygenome. It contains genotype data of more than 20000 individuals of various ethnicities. Genotype data of 3035 individuals with confirmed Indian origin were considered in this study. For polymorphisms not present in the database, genotypes were imputed with IMPUTE2 using 1000 Genomes Phase3 data as reference [37, 38]. Filtration was performed with an imputation certainty score (Info metric) set at 0.3.

2.3 Genotype data for other populations:

Allelic and genotypic frequency data of selected polymorphisms for African (AFR), East Asian (EAS), European (EUR), South Asian (SAS), and American (AMR) populations were taken from 1000 Genomes Phase 3 data [38].

2.4 Statistical analysis:

Polymorphisms having minor allele frequency (MAF) greater than 0.05 in the Indian population (study population) and are in Hardy-Weinberg equilibrium (HWE) ($p > 0.001$) in the Indian population were considered. Pearson's chi-square test was conducted to compare allele frequencies between the Indian population and other populations (AFR, AMR, EUR, EAS, SAS). False discovery rate (FDR) was applied to correct for multiple comparisons. These statistical tests were done with the R packages HardyWeinberg and stats [39]. LDLink tool [40] was used to calculate linkage disequilibrium (LD) among the polymorphisms.

2.5 eQTL data:

To analyze the effect of polymorphisms on gene expressions, expression quantitative trait loci (eQTL) data from publicly available GTEx Project portal was used [41]

3 RESULTS

Out of 1974 shortlisted polymorphisms, 936 polymorphisms had genotype information, either from GenomeDBTM or from imputation. Among them, 670 polymorphisms that had $MAF \geq 0.05$ in the Indian population were considered for further analysis. Followed by this, 589 polymorphisms that were in HWE ($p > 0.001$) were selected. Their allele frequencies in the Indian population were compared with those in other populations using Pearson's chi-square test of significance (Supplementary File 1, Supplementary Table 1). 421 polymorphisms had significant differences ($FDR \leq 0.01$) in at least three populations with respect to the Indian population (Supplementary File 1, Supplementary Table 2). To rule out redundancy, LD blocks were obtained, and finally, 128 representative polymorphisms were considered to discuss in detail (Supplementary File 2).

Polymorphisms were categorized based on their effect on susceptibility to COVID-19, immune response to SARS-CoV2 infection, COVID-19 severity, mortality related to COVID-19, and comorbidities. Fifty polymorphisms directly or indirectly associated with COVID-19 susceptibility

(Table 1), eighteen polymorphisms implicated in the immune response to SARS-CoV2 infection (Table 2), fifty-eight polymorphisms directly or indirectly associated with COVID-19 severity (Table 3), nine polymorphisms associated with COVID-19 related mortality/fatal outcomes (Table 4), and twelve polymorphisms associated with comorbidities of COVID-19 (Table 5) were analyzed.




Figure 1 Comparison of populations based on the number of variants with highest / lowest risk allele frequency related to (A) Susceptibility to COVID-19, (B) COVID-19 severity, and (C) COVID-19 related mortality or fatal outcomes. IND – India, EUR – Europe, AMR

Comparing the risk allele frequencies of a variant between multiple populations can help gain insight into relative genetic predisposition to the associated condition at the population level [42, 43]. In the absence of case-control studies, determining the number of risk variants for different populations might help understand the cumulative genetic effect, hence simplifying the comparison. Here, we applied this approach to ‘COVID-19 susceptibility’, ‘COVID-19 severity’ and ‘COVID-19 related mortality’ categories. Risk conferring variants were assigned to the populations where their frequencies were either highest or lowest. For each population, the number of variants with the highest risk allele frequency and lowest risk allele frequency was counted (Supplementary File 1, Supplementary Table 3). In the ‘COVID-19 susceptibility’ category, the number of variants with the

highest risk allele frequency was less than the variants with the lowest risk allele frequency in the IND population. A similar trend was observed in EAS and AFR populations. However, an opposite trend was observed in EUR and AMR populations (Fig. 1A). In IND and AFR populations, COVID-19 severity-related variants with the highest risk allele frequencies were more than the lowest frequency variants, while in EAS, EUR, and AMR populations this was found to be opposite (Fig. 1B). The number of variants associated with COVID-19 related mortality and having the highest risk allele frequency was less than the variants with the lowest risk allele frequency in IND, EAS, and AFR populations, while in SAS and AMR only the highest frequency variants were observed (Fig. 1C).

4 DISCUSSION

4.1 COVID-19 susceptibility

SARS-CoV-2 gains entry into human cells by binding its spike protein to ACE2 receptors. ACE2, a part of the renin-angiotensin-aldosterone system (RAAS), is crucial in regulating blood pressure and maintaining electrolyte balance in the body, physiology of the heart, kidneys, and lungs [44, 45]. Genetic variations in ACE2 are known to be associated with its increased expression levels in COVID-19 patients. These variants affect ACE2 transcription/translation and also alter binding affinity to SARS-CoV2 spike protein, thereby affecting the susceptibility to SARS-CoV-2 infection [46, 47]. Six ACE2 polymorphisms (rs2285666 [A], rs4240157 [T], rs4646188 [G], rs2158083 [T], rs1978124 [C] and rs233574 [T]), which are known to be associated with increased ACE2 expression, were found to have allele frequencies significantly different in Indian population as compared to others [48, 49, 41, 50, 51, 52]. Their effect allele frequencies in Indian population are 0.459, 0.69, 0.062, 0.76, 0.724 and 0.176, respectively (Table 1). For four of these variants, effect allele frequencies in EAS are highest suggesting that the EAS population might be predisposed to an increased susceptibility to COVID-19. In addition, the frequencies of rs1996225 [T] and rs4060 [A] of CA5BP1 gene and rs1893217 [G] of PTPN2 gene associated with increased expression of ACE2 are also highest in EAS. IND population has intermediate frequencies for most of these variants indicating moderate susceptibility, while EUR has the lowest frequencies indicating reduced susceptibility.

ACE (angiotensin-converting enzyme) is a vital part of the vascular system. It negatively regulates ACE2 and causes vasoconstriction. Alu Insertion in the ACE coding region inhibits ACE expression, while deletion promotes ACE expression. Increased ACE2 expression is observed when homozygous Alu insertion is present in the ACE gene and vice-versa. rs4343 is in high LD with this Alu element and thus used as its tag SNP [53]. The A and G alleles of rs4343 correspond to Alu insertion and deletion, respectively [54]. Thus A allele signifies reduced ACE expression and consequently increased ACE2 expression, potentially leading to increased SARS-CoV-2 susceptibility. In Indians, the frequency of the A allele (0.604) is significantly higher than Europeans (0.435) but lesser than other populations (Table 1).

On infection with SARS-CoV-2, the ADAM17 shedding is activated, leading to the release of ACE2 from the cell membrane into serum – thus inhibiting the virus infection. But, this effect would be compromised, if the infection rate is high [55, 56, 57, 58]. Thus ADAM17 mediated ACE2 levels may modulate COVID-19 susceptibility. ADAM17 releases the precursor TNF- α from the membrane to its active form – which is a crucial player in triggering an inflammatory response, leading to cytokine storm and is associated with severe lung damage in COVID-19 patients [59,60]. Thus,

ADAM17 might be playing role in ACE2 mediated COVID-19 susceptibility and TNF- α mediated COVID-19 severity. rs55790676 [G] and rs1524668 [C] associated with decreased ADAM17 expression have high frequencies in IND population (0.925 and 0.403, respectively), lesser only than EAS, indicating increased susceptibility of COVID-19 in IND population.

212

FURIN is an endoprotease that is implicated in cleaving the SARS-CoV2 spike protein at the S1/S2 site and this cleavage is crucial for viral entry into pulmonary cells [61]. Increased FURIN expression affects monocyte adhesion and transendothelial migration [62] that can lead to tissue damage which is seen in severe COVID-19 patients [63]. In this study, three genetic variants that affect FURIN expression were identified whose allele frequencies are significantly different in the IND population. rs4702 [A] and rs4932178 [T], present in FURIN coding region, are associated with increased FURIN expression [64, 41]. It was also found that rs4702 [A] is associated with increased SARS-CoV2 infection [65]. The frequency of rs4702 [A] in IND (0.499) is one of the lowest suggesting relatively lesser COVID-19 susceptibility in the IND population. The frequency of rs4932178 [T] in the IND population (0.276) is intermediate as compared to others, indicating moderate COVID-19 susceptibility in IND. rs17514846 [A] is associated with the increased FURIN expression in vascular endothelial cells, where it affects monocyte adhesion and transendothelial migration [62]. Recruitment of monocytes and their transendothelial migration can lead to tissue damage which is seen in severe COVID-19 patients [63, 66]. The frequency of rs17514846 [A] in IND (0.371) is significantly higher than EAS and AMR populations and lesser than EUR (Table 3).

IFITM-family proteins are major players in antiviral responses [67]. Severe inflammation and enhanced activation of natural killer cells are observed in influenza-infected IFITM3 deficient mice [68]. IFITM3 is up-regulated in SARS-CoV2 infected lung epithelial cells of COVID-19 patients [69], and IFITM3 seems to restrict SARS-CoV2 infection by modulating the cell membrane properties [70]. This indicates that IFITM3 might be modulating susceptibility to SARS-CoV2 infection. rs11246066 [A] allele is associated with increased IFITM3 expression in whole blood and it is also an eQTL of other IFITM family genes in multiple tissues [71]. rs11246066 [A] allele frequency in the Indian population (0.189) is significantly greater only than the African population. rs9666637 [T] and rs7931303 [G] are associated with increased IFITM2 expression. rs9666637 [T] allele frequency in the Indian population (0.912) is highest among all populations, while rs7931303 [G] allele frequency in the Indian population (0.398) is higher only than AFR. Considering the significance of the IFITM family, Indian population might be less susceptible to COVID-19 due to rs9666637 [T].

CTSL gene is involved in many biological processes such as antigen processing and presentation, proteolysis, macrophage apoptotic process, and immune response. It is associated with many diseases such as cancer, diabetes, kidney failure, and viral infections [72]. It regulates viral entry into host cells and is up-regulated during COVID-19 infection suggesting its potential role in COVID-19 susceptibility and severity [72, 73]. rs3128509 [G] is associated with decreased CTSL expression in various tissues [41] and its frequency is significantly lesser in Indians (0.809) compared to African and East Asian populations but greater than European and American populations. This suggests that the Indian population might be more susceptible to COVID-19 than European and American populations but lesser than African and East populations.

Progesterone acts as a potent immunomodulator in regulating innate and adaptive immune responses and vascular system functions. Progesterone receptors (PGRs) are intracellular receptors that on

binding to progesterone or its derivative regulate target gene expression. An Alu insertion in intron 7 of the PGR gene reduces transcript stability, consequently affecting PGR protein structure and function [74]. As a result of this insertion, PGR modulated differential expression of ACE2 may potentially affect SARS-CoV2 infection susceptibility. This Alu insertion is in complete LD with rs1042838. A and G alleles of rs1042838 correspond to Alu insertion and deletion, respectively [53]. The frequency of rs1042838 [A] in IND (0.078) is significantly lesser than AMR (0.137) and EUR (0.179) populations while greater than AFR (0.006) and EAS (0.01) populations.

TMPRSS2 is a serine protease that plays an important role in SARS-COV2 entry into the host cell. The viral spike (S) protein on binding to ACE2 on the host cell is cleaved at its S1/S2 position by TMPRSS2 thus facilitating viral entry into the host cell [75]. Increased SARS-CoV2 infection correlates with increased TMPRSS2 expression [76]. Eleven polymorphisms (rs35477708 [GA], rs468259 [C], rs363981 [T], rs1638369 [T], rs469288 [G], rs468699 [C], rs462698 [A], rs8134378 [G], rs467375 [A], rs4818239 [C], rs35899679 [A]) whose allele frequencies are significantly in Indian population are associated with increased TMPRSS2 expression [77, 64, 47, 41]. Except for rs8134378 [G], frequencies of remaining variants are highest in EUR and lowest in EAS, suggesting EUR might be at increased susceptibility of COVID-19 while EAS at lowest. Their frequencies in IND are intermediate thus potentially conferring moderate susceptibility in the IND population.

Zinc deficiency is associated with increased COVID-19 susceptibility in the Asian population [78]. Among the genetic variants associated with decreased zinc levels (rs2120019 [C], rs1532423 [G], rs4826508 [C]) and thereby increased susceptibility to COVID-19, rs1532423 [G] from CA1 gene and rs4826508 [C] from the NBDY gene have the lowest frequencies in IND (0.494 and 0.273, respectively), which might be conferring reduced susceptibility to COVID-19 in Indian population. However, rs2120019 [C] from the PPCDC gene might be having an opposite effect as its frequency in IND (0.62) is highest.

4.2 Immune response to SARS-CoV2 infection

IFIH1 gene encodes a protein that recognizes the viral RNA and initiates immune and proinflammatory responses. rs1990760 [T], which is present in the IFIH1 coding region, is associated with autoimmune disorders and protects against viral infection [79]. T allele frequency in Indians is 0.516, second only to Europeans (Table 2). Thus, this might be conferring increased protection to the Indian population against viral infections, including SARS-CoV2.

The chemokines CCL5, CCL4, and CCL3 play an important role in inflammation where they recruit immune cells [80, 81]. They are expressed during respiratory viral infections, and their expression levels are associated with disease severity [82, 83, 84]. In severely affected COVID-19 patients, their expression levels are significantly high, leading to liver toxicity and kidney failure, which are the most common complications associated with COVID-19 infection [82, 83, 84, 85]. rs2526327 [A] in RDM1 gene, rs1994182 [G] in MMP28 gene, rs3826404 [G] in MMP28 gene, rs2107538 [T] and rs3817655 [T] in CCL5 genes are associated with decreased CCL5 expression in whole blood [71] while rs4239252 [A] in TAF15 gene is associated with increased expression of CCL5 in whole blood [71]. All of these alleles are minor alleles in the Indian population. rs3817655, which lies in the CCL5 coding gene, is also associated with SARS-COV susceptibility [42]. The frequency of rs3817655 [T] allele in the Indian population (0.127) is least as compared to other populations.

295 4.3 COVID-19 severity

296 IGFBP2 is involved in the regulation of insulin-like growth factor receptor signaling pathways, and
297 its expression level is used as a marker for many cancers. The intronic variant rs2270360 [A] in the
298 IGFBP2 gene was found to be associated with increased COVID-19 severity [86]. The risk allele [A]
299 frequency in the Indian population is 0.927 which is significantly higher than other populations,
300 indicating the predisposition of the Indian population to the severity of the disease.

301 Low calcium levels in the serum are associated with COVID-19 severity, and maintaining proper
302 calcium is a prerequisite to managing COVID-19 in the initial infection stage. RYR3 is a part of the
303 calcium channel complex and releases calcium for intracellular activities [87]. rs2229117 [G] in the
304 RYR3 gene is shown to be associated with increased COVID-19 severity [86]. G allele frequency in
305 the Indian population (0.913) is higher than American and European populations but lesser than
306 African and East Asian populations (Table 3). Thus this variant might be conferring a moderate risk
307 of COVID-19 severity in the Indian population.

308 CCL2 and CCR1 play major roles in immune and inflammatory responses. CCL2 is a chemo-
309 attractant cytokine that modulates the recruitment of monocytes, T cells, B cells, natural killer cells,
310 macrophages, and dendritic cells [88]. Increased CCL2 levels are observed in severe COVID-19
311 patients as compared to less severe COVID-19 patients [89]. CCR1 is a chemokine receptor that is
312 strongly expressed in monocytes and macrophages and promotes their infiltration into the lungs in
313 severe COVID-19 cases [90]. rs1024611 [G] and rs1015164 [G] alleles are associated with increased
314 CCL2 expression [91] and increased CCR1 expression in whole blood [63], respectively. rs1024611
315 [G] frequency in Indians (0.316) is significantly greater than only the African population, while
316 rs1015164 [G] frequency in Indians (0.753) is significantly greater than only the European
317 population (Table 3).

318 MX1 is known to be implicated in the generation of protective immune responses against influenza
319 infection [92]. Increased MX1 expression in the nasopharynx of COVID-19 patients is observed to
320 be proportional to SARS-CoV2 viral load. However, its expression seems to reduce with increased
321 age, suggesting inadequate antiviral immune response in older adults causing severe COVID-19 [92].
322 These results suggest that increased expression of MX1 might be restricting the COVID-19 severity.
323 Six polymorphisms (rs35477708 [G], rs468259 [G], rs363981 [G], rs1638369 [G], rs469288 [A],
324 rs468699 [T], rs462698 [G]) associated with decreased MX1 expression [41, 47] might be increasing
325 risk of COVID-19 severity. Effect allele frequencies of each of these variants are highest in EAS and
326 lowest in the EUR population. This indicates that the EAS population might be vulnerable to
327 increased risk of COVID-19 severity, while EUR and IND populations might be at reduced and
328 moderate risk, respectively.

329 TNF encodes a proinflammatory cytokine secreted by macrophages is a major player contributing to
330 the development of cytokine storms. rs1800630 [A] in the TNF gene is associated with an increased
331 risk of developing acute respiratory distress syndrome (ARDS) [93]. The frequency of risk allele [A]
332 in the Indian population (0.283) is highest as compared to other populations, suggesting that the
333 allele might be conferring increased risk of COVID-19 severity to the Indian population.

334 AHSR levels are critical for regulating macrophage deactivation. Decreased AHSR leads to impaired
335 macrophage deactivation thus causing excess pro-inflammatory cytokine release in SARS-COV
336 infection. rs2248690 [T] is associated with increased AHSR levels and decreased SARS-COV
337 infection severity [94]. T allele frequency in the Indian population is 0.17 which is the least as

compared to other populations, indicating that the Indian population might be at an increased risk of COVID-19 severity.

rs10735079 in OAS gene cluster (OAS1, OAS2, OAS3) is associated with antiviral mechanisms by producing 2',5'-oligoadenylate (2-5A), which is a mediator in the antiviral process. This mediator activates RNaseL which degrades double-stranded RNA of corona virus [95]. rs10735079 [A] allele is associated with an increased risk of severe COVID-19. rs10735079 [A] allele corresponds to lower OAS1 activity and higher odds of severe COVID-19 [95]. A allele frequency in the Indian population (0.698) is lower than African, American, and East Asian populations but greater than Europeans, suggesting that the Indian population might be at a reduced risk of COVID-19 severity.

Decreased levels of E-selectin and IL-3Ra proteins and increased levels of B3GN2 and C1GLC proteins are associated with increased COVID-19 severity [96]. rs2519093 [T] is associated with decreased E-selectin and IL-3Ra protein levels and increased B3GN2 and C1GLC protein levels. Thus, rs2519093 [T] might be increasing COVID-19 severity through modulating these protein levels. T allele frequency in the Indian population (0.128) (Table 3), is greater than only the African population, suggesting that Indian population might be at a reduced risk of COVID-19 severity.

Vitamin D deficiency is associated with COVID-19 positivity and severity [97, 98]. GC gene encodes a protein that binds to vitamin D and transports it to targeted tissues. rs1155563 [C] allele, that is present in the GC gene, is associated with decreased serum vitamin-D levels [99], and its frequency in the Indian population (0.29) is greater than that of African, American, and European populations (Table 3). This suggests that rs1155563 [C] might be increasing COVID-19 susceptibility and severity in the Indian population through reduced vitamin-D levels.

4.4 COVID-19 related mortality or fatal outcomes

Kim YC and Jeong BH [71] found the frequencies of T allele of rs2074192 in the ACE2 gene, and G allele of rs2298659 in the TMPRSS2 gene to be positively correlated with case fatality rate. Indians have lowest frequency of rs2074192 [T] (0.222) compared to Africans (0.351), Americans (0.405), East Asians (0.43) and Europeans (0.432). But they have highest frequency of rs2298659 [G] (0.834) compared to Africans (0.825), Americans (0.782), Europeans (0.77) and East Asians (0.751). Indians have lesser frequency of G allele of rs6598045 in the IFITM3 gene (0.159), which is associated with decreased case fatality rate, compared to Africans (0.299) and Americans (0.222).

DES/SPEG genes code for muscle-specific proteins and mutations in these genes are involved with cardiomyopathies [100, 101]. Acute damage to the heart is a common complication in COVID-19 patients. A allele of rs71040457 that is located downstream of the DES and upstream of the SPEG genes was found to be associated with an increased risk of COVID-19 mortality in the white British ancestry population [102]. While East Asians have the lowest frequency of this allele (0.177), Indians have a lesser frequency (0.276) compared to European (0.376), American (0.385), and African (0.939) populations.

SLC39A10 gene plays an important role in mediating immune cell homeostasis. It has been reported to facilitate anti-apoptotic signaling during early B-cell development, modulate B-cell receptor signal strength, and control macrophage survival. rs113892140 located in this gene is associated with an increased risk of COVID-19 mortality [102]. Risk allele [A] frequency in the Indian population is

0.078 (Table 4), which is significantly greater than only the European population (0.046). Its frequency is highest in the African population (0.256).

4.5 COVID-19 related comorbidities

Twelve polymorphisms associated with comorbidities of COVID-19 were also analyzed (Table 5). Hypertension, coronary artery disease, type 2 diabetes are among the major comorbidities of COVID-19 severity. rs2074192 [T] is associated with an increased risk of developing hypertension [49]. T allele frequency in the Indian population (0.222) is least as compared to other populations.

5 CONCLUSION

The potential role of several polymorphisms in COVID-19 susceptibility and severity suggests that host genetics plays an important role in the pathology and progression of the infection. We found multiple genetic variants that might be affecting the COVID-19 susceptibility, immune response, severity, and mortality. Some of these variants were observed in genetic association studies, while others were found to be relevant based on gene regulation and signaling pathways.

COVID-19 positivity rate in India is one of the least in the world despite India being the second most populated nation [154, 155]. Due to the high population density in India, the spread of an airborne pathogen can be limited only to a certain extent [103]. Hence, a low COVID-19 positivity rate in India might be due to the lower genetic predisposition of Indians to COVID-19 susceptibility. The fatality rate of COVID-19 in India was relatively high during the peak phases of the first and second waves. However, when the peaks subsided the fatality rate reduced significantly. Inadequate medical facilities seem to be one of the major reasons which caused preventable deaths during these periods. [104]. Thus, the role of genetics in COVID-19 severity risk in the Indian population remains unclear. More detailed studies are warranted to confirm the COVID-19 related relevance of the variants discussed in this article. The current study will act as a good source to shortlist variants/genes for conducting genetic association studies to assess COVID-19 susceptibility, its severity, and mortality.

6 REFERENCES

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
3. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil Med Res*. 2020;7(1):11. Published 2020 Mar 13. doi:10.1186/s40779-020-00240-0

- 414 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
415 coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet.
416 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
- 417 5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
418 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.
419 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
- 420 6. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with
421 coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar
422 31;368:m1295]. BMJ. 2020;368:m1091. Published 2020 Mar 26. doi:10.1136/bmj.m1091
- 423 7. Giacomelli A, Pezzati L, Conti F, et al. Self-reported Olfactory and Taste Disorders in
424 Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin
425 Infect Dis. 2020;71(15):889-890. doi:10.1093/cid/ciaa330
- 426 8. Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk
427 factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 2021;76(2):533-
428 550. doi:10.1111/all.14496
- 429 9. Rubin SJS, Falkson SR, Degner NR, Blish C. Clinical characteristics associated with COVID-
430 19 severity in California. J Clin Transl Sci. 2020;5(1):e3. Published 2020 Apr 16.
431 doi:10.1017/cts.2020.40
- 432 10. Riccardo F, Ajelli M, Andrianou XD, et al. Epidemiological characteristics of COVID-19
433 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31
434 March 2020. Euro Surveill. 2020;25(49):2000790. doi:10.2807/1560-7917.ES.2020.25.49.2000790
- 435 11. Cao M, Zhang D, Wang Y, et al. Clinical Features of Patients Infected with the 2019 Novel
436 Coronavirus (COVID-19) in Shanghai, China. Preprint. medRxiv. 2020;2020.03.04.20030395.
437 Published 2020 Mar 6. doi:10.1101/2020.03.04.20030395
- 438 12. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on
439 Severity and Mortality. Front Public Health. 2020;8:152. Published 2020 Apr 29.
440 doi:10.3389/fpubh.2020.00152
- 441 13. Guo L, Shi Z, Zhang Y, et al. Comorbid diabetes and the risk of disease severity or death
442 among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Res Clin Pract.
443 2020;166:108346. doi:10.1016/j.diabres.2020.108346
- 444 14. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of
445 COVID-19 Patients Hospitalized in the United States [published correction appears in J Diabetes Sci
446 Technol. 2020 Jun 10;:1932296820932678]. J Diabetes Sci Technol. 2020;14(4):813-821.
447 doi:10.1177/1932296820924469
- 448 15. Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe
449 disease: a multicenter retrospective observational study. Hypertens Res. 2020;43(8):824-831.
450 doi:10.1038/s41440-020-0485-2

- 451 16. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
452 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA.
453 2021 Mar 16;325(11):1113]. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
- 454 17. Ran J, Song Y, Zhuang Z, et al. Blood pressure control and adverse outcomes of COVID-19
455 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res.
456 2020;43(11):1267-1276. doi:10.1038/s41440-020-00541-w
- 457 18. Fresán U, Guevara M, Elía F, et al. Independent Role of Severe Obesity as a Risk Factor for
458 COVID-19 Hospitalization: A Spanish Population-Based Cohort Study. Obesity (Silver Spring).
459 2021;29(1):29-37. doi:10.1002/oby.23029
- 460 19. Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with
461 indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020;4(20):4981-
462 4989. doi:10.1182/bloodadvances.2020002623
- 463 20. Pourali F, Afshari M, Alizadeh-Navaei R, Javidnia J, Moosazadeh M, Hessami A.
464 Relationship between blood group and risk of infection and death in COVID-19: a live meta-analysis.
465 New Microbes New Infect. 2020;37:100743. doi:10.1016/j.nmni.2020.100743
- 466 21. Garg I, Srivastava S, Dogra V, et al. Potential association of COVID-19 and ABO blood
467 group: An Indian study. Microb Pathog. 2021;158:105008. doi:10.1016/j.micpath.2021.105008
- 468 22. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights
469 and translational opportunities. Nat Rev Genet. 2021;22(3):137-153. doi:10.1038/s41576-020-00297-
470 6
- 471 23. Di Maria E, Latini A, Borgiani P, Novelli G. Genetic variants of the human host influencing
472 the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and
473 field synopsis. Hum Genomics. 2020;14(1):30. Published 2020 Sep 11. doi:10.1186/s40246-020-
474 00280-6
- 475 24. Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host
476 genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6(1):83. Published
477 2020 Nov 10. doi:10.1038/s41421-020-00231-4
- 478 25. Gómez J, Albaiceta GM, Cuesta-Llavona E, et al. The Interferon-induced transmembrane
479 protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine.
480 2021;137:155354. doi:10.1016/j.cyto.2020.155354
- 481 26. Zhang Y, Qin L, Zhao Y, et al. Interferon-Induced Transmembrane Protein 3 Genetic Variant
482 rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. J Infect Dis.
483 2020;222(1):34-37. doi:10.1093/infdis/jiaa224
- 484 27. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, et al. Genomewide Association
485 Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383(16):1522-1534.
486 doi:10.1056/NEJMoa2020283
- 487 28. Littera R, Campagna M, Deidda S, et al. Human Leukocyte Antigen Complex and Other
488 Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection

489 and Severity of the Disease Course. The Sardinian Experience. *Front Immunol.* 2020;11:605688.
490 Published 2020 Dec 4. doi:10.3389/fimmu.2020.605688

491 29. Yung YL, Cheng CK, Chan HY, et al. Association of HLA-B22 serotype with SARS-CoV-2
492 susceptibility in Hong Kong Chinese patients. *HLA.* 2021;97(2):127-132. doi:10.1111/tan.14135

493 30. Amoroso A, Magistroni P, Vespasiano F, et al. HLA and AB0 Polymorphisms May Influence
494 SARS-CoV-2 Infection and COVID-19 Severity. *Transplantation.* 2021;105(1):193-200.
495 doi:10.1097/TP.0000000000003507

496 31. Saleh A, Sultan A, Elashry MA, et al. Association of TNF- α G-308 a Promoter
497 Polymorphism with the Course and Outcome of COVID-19 Patients [published online ahead of print,
498 2020 Nov 23]. *Immunol Invest.* 2020;1-12. doi:10.1080/08820139.2020.1851709

499 32. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and
500 foe?. *JCI Insight.* 2020;5(15):e140711. Published 2020 Aug 6. doi:10.1172/jci.insight.140711

501 33. Valenti L, Griffini S, Lamorte G, et al. Chromosome 3 cluster rs11385942 variant links
502 complement activation with severe COVID-19 [published correction appears in *J Autoimmun.* 2021
503 Jun;120:102646]. *J Autoimmun.* 2021;117:102595. doi:10.1016/j.jaut.2021.102595

504 34. Srivastava A, Bandopadhyay A, Das D, et al. Genetic Association of ACE2 rs2285666
505 Polymorphism With COVID-19 Spatial Distribution in India. *Front Genet.* 2020;11:564741.
506 Published 2020 Sep 25. doi:10.3389/fgene.2020.564741

507 35. Ravikanth V, Sasikala M, Naveen V, et al. A variant in TMPRSS2 is associated with
508 decreased disease severity in COVID-19. *Meta Gene.* 2021;29:100930.
509 doi:10.1016/j.mgene.2021.100930

510 36. Singh PP, Srivastava A, Sultana GNN, et al. The major genetic risk factor for severe COVID-
511 19 does not show any association among South Asian populations [published correction appears in
512 *Sci Rep.* 2021 Aug 5;11(1):16296]. *Sci Rep.* 2021;11(1):12346. Published 2021 Jun 11.
513 doi:10.1038/s41598-021-91711-4

514 37. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. *G3*
515 (Bethesda). 2011;1(6):457-470. doi:10.1534/g3.111.001198

516 38. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human
517 genetic variation. *Nature.* 2015;526(7571):68-74. doi:10.1038/nature15393

518 39. R Core Team (2020). R: A language and environment for statistical computing. R Foundation
519 for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>

520 40. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
521 haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics.*
522 2015;31(21):3555-3557. doi:10.1093/bioinformatics/btv402

523 41. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.*
524 2013;45(6):580-585. doi:10.1038/ng.2653

525 42. Smatti MK, Al-Sarraj YA, Albagha O, Yassine HM. Host Genetic Variants Potentially
526 Associated With SARS-CoV-2: A Multi-Population Analysis. *Front Genet.* 2020;11:578523.
527 Published 2020 Oct 2. doi:10.3389/fgene.2020.578523

528 43. Secolin R, de Araujo TK, Gonsales MC, et al. Genetic variability in COVID-19-related genes
529 in the Brazilian population. *Hum Genome Var.* 2021;8:15. Published 2021 Apr 2.
530 doi:10.1038/s41439-021-00146-w

531 44. Bhalla V, Blish CA, South AM. A historical perspective on ACE2 in the COVID-19 era. *J*
532 *Hum Hypertens.* 2021;35(10):935-939. doi:10.1038/s41371-020-00459-3

533 45. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of
534 the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol Rev.* 2018;98(1):505-553.
535 doi:10.1152/physrev.00023.2016

536 46. Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms
537 and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. Preprint.
538 bioRxiv. 2020; 2020.04.23.057042v1. Published 2020 April 24. doi: 10.1101/2020.04.23.057042

539 47. Lanjanian H, Moazzam-Jazi M, Hedayati M, et al. SARS-CoV-2 infection susceptibility
540 influenced by ACE2 genetic polymorphisms: insights from Tehran Cardio-Metabolic Genetic Study.
541 *Sci Rep.* 2021;11(1):1529. Published 2021 Jan 15. doi:10.1038/s41598-020-80325-x

542 48. Wu YH, Li JY, Wang C, Zhang LM, Qiao H. The ACE2 G8790A Polymorphism:
543 Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke. *J Clin Lab Anal.*
544 2017;31(2):e22033. doi:10.1002/jcla.22033

545 49. Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces
546 of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. *Mol*
547 *Ther Methods Clin Dev.* 2020;18:321-327. Published 2020 Jun 25. doi:10.1016/j.omtm.2020.06.017

548 50. Brest P, Refae S, Mograbi B, Hofman P, Milano G. Host Polymorphisms May Impact SARS-
549 CoV-2 Infectivity. *Trends Genet.* 2020;36(11):813-815. doi:10.1016/j.tig.2020.08.003

550 51. Paniri A, Hosseini MM, Moballegh-Eslam M, Akhavan-Niaki H. Comprehensive in silico
551 identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations. *Gene*
552 *Rep.* 2021;22:100979. doi:10.1016/j.genrep.2020.100979

553 52. Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility:
554 An in silico analysis. *Mol Genet Genomic Med.* 2021;9(6):e1672. doi:10.1002/mgg3.1672

555 53. Li M, Schifanella L, Larsen PA. Alu retrotransposons and COVID-19 susceptibility and
556 morbidity. *Hum Genomics.* 2021;15(1):2. Published 2021 Jan 4. doi:10.1186/s40246-020-00299-9

557 54. Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an ACE I/D
558 proxy, and an analysis in the British Women's Heart and Health Study (BWHHS). *Dis Markers.*
559 2008;24(1):11-17. doi:10.1155/2008/813679

560 55. Schreiber B, Patel A, Verma A. Shedding light on COVID-19: ADAM17 the missing link?.
561 *American Journal of Therapeutics.* 2021; 28(3),e358-e360.

562 56. Bastolla U, Chambers P, Abia D, García-Bermejo ML, Fresno M. Is Covid-19 severity
563 associated with ACE2 degradation?. Preprint. arXiv. 2021;2102.13210.

564 57. Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase
565 (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-
566 coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem.
567 2005;280(34):30113-30119. doi:10.1074/jbc.M505111200

568 58. Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect on COVID-
569 19. Nephrol Dial Transplant. 2020;35(6):1071-1072. doi:10.1093/ndt/gfaa093

570 59. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol.
571 2010;45(2):146-169. doi:10.3109/10409231003628015

572 60. Zipeto D, Palmeira JDF, Argañaraz GA, Argañaraz ER. ACE2/ADAM17/TMPRSS2
573 Interplay May Be the Main Risk Factor for COVID-19. Front Immunol. 2020;11:576745. Published
574 2020 Oct 7. doi:10.3389/fimmu.2020.576745

575 61. Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein
576 of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020;78(4):779-784.e5.
577 doi:10.1016/j.molcel.2020.04.022

578 62. Yang X, Yang W, McVey DG, et al. FURIN Expression in Vascular Endothelial Cells Is
579 Modulated by a Coronary Artery Disease-Associated Genetic Variant and Influences Monocyte
580 Transendothelial Migration. J Am Heart Assoc. 2020;9(4):e014333. doi:10.1161/JAHA.119.014333

581 63. Meidaninikjeh S, Sabouni N, Marzouni HZ, Bengar S, Khalili A, Jafari R. Monocytes and
582 macrophages in COVID-19: Friends and foes. Life Sci. 2021;269:119010.
583 doi:10.1016/j.lfs.2020.119010

584 64. Ragia G, Manolopoulos VG. Assessing COVID-19 susceptibility through analysis of the
585 genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. Pharmacogenomics.
586 2020;21(18):1311-1329. doi:10.2217/pgs-2020-0092

587 65. Dobrindt K, Hoagland DA, Seah C, et al. Common genetic variation in humans impacts in
588 vitro susceptibility to SARS-CoV-2 infection. Preprint. bioRxiv. 2020;2020.09.20.300574. Published
589 2020 Sep 21. doi:10.1101/2020.09.20.300574

590 66. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-
591 19. Lancet. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5

592 67. Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-Family Proteins: The Cell's First Line of
593 Antiviral Defense. Annu Rev Virol. 2014;1:261-283. doi:10.1146/annurev-virology-031413-085537

594 68. Sun Q, Lei N, Lu J, et al. Interferon-induced Transmembrane Protein 3 Prevents Acute
595 Influenza Pathogenesis in Mice. Biomed Environ Sci. 2020;33(5):295-305. doi:10.3967/bes2020.041

596 69. Hachim MY, Al Heialy S, Hachim IY, et al. Interferon-Induced Transmembrane Protein
597 (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Front Immunol.
598 2020;11:1372. Published 2020 Jun 10. doi:10.3389/fimmu.2020.01372

599 70. Shi G, Kenney AD, Kudryashova E, et al. Opposing activities of IFITM proteins in SARS-
600 CoV-2 infection. *EMBO J*. 2021;40(3):e106501. doi:10.15252/embj.2020106501

601 71. Kim YC, Jeong BH. Strong Correlation between the Case Fatality Rate of COVID-19 and the
602 rs6598045 Single Nucleotide Polymorphism (SNP) of the Interferon-Induced Transmembrane
603 Protein 3 (IFITM3) Gene at the Population-Level. *Genes (Basel)*. 2020;12(1):42. Published 2020 Dec
604 30. doi:10.3390/genes12010042

605 72. Gomes CP, Fernandes DE, Casimiro F, et al. Cathepsin L in COVID-19: From
606 Pharmacological Evidences to Genetics. *Front Cell Infect Microbiol*. 2020;10:589505. Published
607 2020 Dec 8. doi:10.3389/fcimb.2020.589505

608 73. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection
609 in humans and humanized mice and is a promising target for new drug development. *Signal*
610 *Transduct Target Ther*. 2021;6(1):134. Published 2021 Mar 27. doi:10.1038/s41392-021-00558-8

611 74. Romano A, Delvoux B, Fischer DC, Groothuis P. The PROGINS polymorphism of the
612 human progesterone receptor diminishes the response to progesterone. *J Mol Endocrinol*. 2007;38(1-
613 2):331-350. doi:10.1677/jme.1.02170

614 75. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on
615 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*.
616 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

617 76. Sarker J, Das P, Sarker S, Roy AK, Momen AZMR. A Review on Expression, Pathological
618 Roles, and Inhibition of TMPRSS2, the Serine Protease Responsible for SARS-CoV-2 Spike Protein
619 Activation. *Scientifica (Cairo)*. 2021;2021:2706789. Published 2021 Jul 24.
620 doi:10.1155/2021/2706789

621 77. Clinckemalie L, Spans L, Dubois V, et al. Androgen regulation of the TMPRSS2 gene and
622 the effect of a SNP in an androgen response element. *Mol Endocrinol*. 2013;27(12):2028-2040.
623 doi:10.1210/me.2013-1098

624 78. Ali N, Fariha KA, Islam F, et al. Assessment of the role of zinc in the prevention of COVID-
625 19 infections and mortality: A retrospective study in the Asian and European population. *J Med*
626 *Virol*. 2021;93(7):4326-4333. doi:10.1002/jmv.26932

627 79. Gorman JA, Hundhausen C, Errett JS, et al. The A946T variant of the RNA sensor IFIH1
628 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. *Nat*
629 *Immunol*. 2017;18(7):744-752. doi:10.1038/ni.3766

630 80. Maurer M, von Stebut E. Macrophage inflammatory protein-1. *Int J Biochem Cell Biol*.
631 2004;36(10):1882-1886. doi:10.1016/j.biocel.2003.10.019

632 81. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal
633 disease. *Nat Clin Pract Nephrol*. 2007;3(3):164-170. doi:10.1038/ncpneph0418

634 82. Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation.
635 *Expert Opin Ther Targets*. 2013;17(12):1439-1460. doi:10.1517/14728222.2013.837886

636 83. Patterson BK, Seethamraju H, Dhody K, et al. Disruption of the CCL5/RANTES-CCR5
637 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.
638 Preprint. medRxiv. 2020;2020.05.02.20084673. Published 2020 May 5.
639 doi:10.1101/2020.05.02.20084673

640 84. Coperchini F, Chiovato L, Ricci G, Croce L, Magri F, Rotondi M. The cytokine storm in
641 COVID-19: Further advances in our understanding the role of specific chemokines involved.
642 Cytokine Growth Factor Rev. 2021;58:82-91. doi:10.1016/j.cytogfr.2020.12.005

643 85. Patterson BK, Seethamraju H, Dhody K, et al. CCR5 inhibition in critical COVID-19 patients
644 decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in
645 plasma by day 14. Int J Infect Dis. 2021;103:25-32. doi:10.1016/j.ijid.2020.10.101

646 86. Dite GS, Murphy NM, Allman R. An integrated clinical and genetic model for predicting risk
647 of severe COVID-19: A population-based case-control study. PLoS One. 2021;16(2):e0247205.
648 Published 2021 Feb 16. doi:10.1371/journal.pone.0247205

649 87. Zhou X, Chen D, Wang L, et al. Low serum calcium: a new, important indicator of COVID-
650 19 patients from mild/moderate to severe/critical [published online ahead of print, 2020 Nov 30].
651 Biosci Rep. 2020;40(12):BSR20202690. doi:10.1042/BSR20202690

652 88. Gschwandtner M, Derler R, Midwood KS. More Than Just Attractive: How CCL2 Influences
653 Myeloid Cell Behavior Beyond Chemotaxis. Front Immunol. 2019;10:2759. Published 2019 Dec 13.
654 doi:10.3389/fimmu.2019.02759

655 89. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19:
656 An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth
657 Factor Rev. 2020;53:25-32. doi:10.1016/j.cytogfr.2020.05.003

658 90. Stikker B, Stik G, Hendriks RW, Stadhouders R. Severe COVID-19 associated variants
659 linked to chemokine receptor gene control in monocytes and macrophages. Preprint. bioRxiv.
660 2021;2021.01.22.427813. Published 2021 Jun 11. doi:10.1101/2021.01.22.427813

661 91. Pham MH, Bonello GB, Castiblanco J, et al. The rs1024611 regulatory region polymorphism
662 is associated with CCL2 allelic expression imbalance. PLoS One. 2012;7(11):e49498.
663 doi:10.1371/journal.pone.0049498

664 92. Bizzotto J, Sanchis P, Abbate M, et al. SARS-CoV-2 Infection Boosts MX1 Antiviral
665 Effector in COVID-19 Patients. iScience. 2020;23(10):101585. doi:10.1016/j.isci.2020.101585

666 93. Azevedo ZM, Moore DB, Lima FC, et al. Tumor necrosis factor (TNF) and lymphotoxin-
667 alpha (LTA) single nucleotide polymorphisms: importance in ARDS in septic pediatric critically ill
668 patients. Hum Immunol. 2012;73(6):661-667. doi:10.1016/j.humimm.2012.03.007

669 94. Zhu X, Wang Y, Zhang H, et al. Genetic variation of the human α -2-Heremans-Schmid
670 glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection. PLoS One.
671 2011;6(8):e23730. doi:10.1371/journal.pone.0023730

672 95. Pairo-Castineira, Erola, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S
673 et al. Nature. 2021; 591(7848): 92-98. doi:10.1038/s41586-020-03065-y. Epub 2020 Dec 11.

- 674 96. Zhu J, Wu C, Wu L. Associations Between Genetically Predicted Protein Levels and COVID-
675 19 Severity. *J Infect Dis.* 2021;223(1):19-22. doi:10.1093/infdis/jiaa660
- 676 97. Demir M, Demir F, Aygun H. Vitamin D deficiency is associated with COVID-19 positivity
677 and severity of the disease. *J Med Virol.* 2021;93(5):2992-2999. doi:10.1002/jmv.26832
- 678 98. Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the
679 severity of COVID-19?. *Clin Med (Lond).* 2020;20(4):e107-e108. doi:10.7861/clinmed.2020-0301
- 680 99. Galmés S, Serra F, Palou A. Current State of Evidence: Influence of Nutritional and
681 Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework. *Nutrients.*
682 2020;12(9):2738. Published 2020 Sep 8. doi:10.3390/nu12092738
- 683 100. Agrawal PB, Pierson CR, Joshi M, et al. SPEG interacts with myotubularin, and its deficiency
684 causes centronuclear myopathy with dilated cardiomyopathy. *Am J Hum Genet.* 2014;95(2):218-226.
685 doi:10.1016/j.ajhg.2014.07.004
- 686 101. Brodehl A, Gaertner-Rommel A, Milting H. Molecular insights into cardiomyopathies
687 associated with desmin (DES) mutations. *Biophys Rev.* 2018;10(4):983-1006. doi:10.1007/s12551-
688 018-0429-0
- 689 102. Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of
690 COVID-19 related mortality from UK Biobank data. Preprint. medRxiv. 2020;2020.11.05.20226761.
691 Published 2020 Nov 9. doi:10.1101/2020.11.05.20226761
- 692 103. Bhadra A, Mukherjee A, Sarkar K. Impact of population density on Covid-19 infected and
693 mortality rate in India [published online ahead of print, 2020 Oct 14]. *Model Earth Syst Environ.*
694 2020;1-7. doi:10.1007/s40808-020-00984-7
- 695 104. Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in
696 India. *Lancet Respir Med.* 2021;9(9):e93-e94. doi:10.1016/S2213-2600(21)00312-X
- 697 105. Ghafouri-Fard S, Noroozi R, Vafae R, et al. Effects of host genetic variations on response to,
698 susceptibility and severity of respiratory infections. *Biomed Pharmacother.* 2020;128:110296.
699 doi:10.1016/j.biopha.2020.110296
- 700 106. Sainz J, Lupiáñez CB, Segura-Catena J, et al. Dectin-1 and DC-SIGN polymorphisms
701 associated with invasive pulmonary Aspergillosis infection. *PLoS One.* 2012;7(2):e32273.
702 doi:10.1371/journal.pone.0032273
- 703 107. Avendaño-Tamayo E, Rúa A, Parra-Marín MV, et al. Evaluation of variants in IL6R, TLR3,
704 and DC-SIGN genes associated with dengue in sampled Colombian population. Evaluación de
705 variantes en los genes IL6R, TLR3 y DC-SIGN asociadas con dengue en una población colombiana
706 muestreada. *Biomedica.* 2019;39(1):88-101. Published 2019 Mar 31.
707 doi:10.7705/biomedica.v39i1.4029
- 708 108. Vargas-Alarcón G, Posadas-Sánchez R, Ramírez-Bello J. Variability in genes related to
709 SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its
710 potential use in association studies. *Life Sci.* 2020;260:118313. doi:10.1016/j.lfs.2020.118313

- 711 109. Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The Immune Response and
712 Immunopathology of COVID-19. *Front Immunol.* 2020;11:2037. Published 2020 Aug 26.
713 doi:10.3389/fimmu.2020.02037
- 714 110. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in
715 COVID-19. *Acta Diabetol.* 2020;57(7):779-783. doi:10.1007/s00592-020-01539-z
- 716 111. Nelson CP, Sama IE, Codd V, et al. Genetic Associations With Plasma Angiotensin
717 Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. *Circulation.*
718 2020;142(11):1117-1119. doi:10.1161/CIRCULATIONAHA.120.049007
- 719 112. Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E. The transcription factor
720 HNF1 α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from
721 evolutionarily conserved promoter motifs. *Biochim Biophys Acta.* 2013;1829(11):1225-1235.
722 doi:10.1016/j.bbagr.2013.09.007
- 723 113. Iyer GR, Samajder S, Zubeda S, et al. Infectivity and Progression of COVID-19 Based on
724 Selected Host Candidate Gene Variants. *Front Genet.* 2020;11:861. Published 2020 Sep 4.
725 doi:10.3389/fgene.2020.00861
- 726 114. Prelli Bozzo C, Nchioua R, Volcic M, et al. IFITM proteins promote SARS-CoV-2 infection
727 and are targets for virus inhibition in vitro. *Nat Commun.* 2021;12(1):4584. Published 2021 Jul 28.
728 doi:10.1038/s41467-021-24817-y
- 729 115. Zhang Y, Yang H, Li S, Li WD, Wang J, Wang Y. Association analysis framework of genetic
730 and exposure risks for COVID-19 in middle-aged and elderly adults. *Mech Ageing Dev.*
731 2021;194:111433. doi:10.1016/j.mad.2021.111433
- 732 116. Evans DM, Zhu G, Dy V, et al. Genome-wide association study identifies loci affecting blood
733 copper, selenium and zinc. *Hum Mol Genet.* 2013;22(19):3998-4006. doi:10.1093/hmg/ddt239
- 734 117. Spalinger MR, Hai R, Li J, et al. Identification of a Novel Susceptibility Marker for SARS-
735 CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in
736 Human/Mouse Cells. Preprint. *bioRxiv.* 2020;2020.12.09.416586. Published 2020 Dec 9.
737 doi:10.1101/2020.12.09.416586
- 738 118. Paniri A, Hosseini MM, Akhavan-Niaki H. First comprehensive computational analysis of
739 functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different
740 populations. *J Biomol Struct Dyn.* 2021;39(10):3576-3593. doi:10.1080/07391102.2020.1767690
- 741 119. Karakas Celik S, Cakmak Genc G, Dursun A. A bioinformatic approach to investigating
742 cytokine genes and their receptor variants in relation to COVID-19 progression. *Int J Immunogenet.*
743 2021;48(2):211-218. doi:10.1111/iji.12522
- 744 120. Stairiker CJ, van Meurs M, Leon LG, et al. Heatr9 is an infection responsive gene that affects
745 cytokine production in alveolar epithelial cells. *PLoS One.* 2020;15(7):e0236195. Published 2020 Jul
746 17. doi:10.1371/journal.pone.0236195
- 747 121. Montoya MC, Sancho D, Bonello G, et al. Role of ICAM-3 in the initial interaction of T
748 lymphocytes and APCs. *Nat Immunol.* 2002;3(2):159-168. doi:10.1038/ni753

749 122. Hashemi SMA, Thijssen M, Hosseini SY, Tabarraei A, Pourkarim MR, Sarvari J. Human
750 gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
751 Arch Virol. 2021;166(8):2089-2108. doi:10.1007/s00705-021-05070-6

752 123. Maiti AK. The African-American population with a low allele frequency of SNP rs1990760
753 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19
754 infection. Immunogenetics. 2020;72(6-7):387-391. doi:10.1007/s00251-020-01174-6

755 124. Chong WP, Ip WK, Tso GH, et al. The interferon gamma gene polymorphism +874 A/T is
756 associated with severe acute respiratory syndrome. BMC Infect Dis. 2006;6:82. Published 2006 May
757 4. doi:10.1186/1471-2334-6-82

758 125. Farhan S, Nadeem M, Ahmed RS, Nadeem MT, Arshad MS, and Ullah A. Studying the
759 impact of nutritional immunology underlying the modulation of immune responses by nutritional
760 compounds—a review. Food and agricultural immunology. 2016; 27(2):205-229. doi:
761 org/10.1080/09540105.2015.1079600

762 126. Shane B, Pangilinan F, Mills JL, et al. The 677C→T variant of MTHFR is the major genetic
763 modifier of biomarkers of folate status in a young, healthy Irish population. Am J Clin Nutr.
764 2018;108(6):1334-1341. doi:10.1093/ajcn/nqy209

765 127. Schmiedel BJ, Singh D, Madrigal A, et al. Impact of Genetic Polymorphisms on Human
766 Immune Cell Gene Expression. Cell. 2018;175(6):1701-1715.e16. doi:10.1016/j.cell.2018.10.022

767 128. Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial
768 activation is a good predictor factor for intensive care unit admission of COVID-19 patients.
769 Angiogenesis. 2020;23(4):611-620. doi:10.1007/s10456-020-09730-0

770 129. Nagy B Jr, Fejes Z, Szentkereszty Z, et al. A dramatic rise in serum ACE2 activity in a
771 critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412-414. doi:10.1016/j.ijid.2020.11.184

772 130. Hamet P, Pausova Z, Attaoua R, et al. SARS-CoV-2 Receptor ACE2 Gene Is Associated with
773 Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. Am J
774 Hypertens. 2021;34(4):367-376. doi:10.1093/ajh/hpaa223

775 131. Wooster L, Nicholson CJ, Sigurslid HH, Cardenas CLL, Malhotra R. Polymorphisms in the
776 ACE2 locus associate with severity of COVID-19 infection. Preprint. medRxiv. 2020. doi:
777 <https://doi.org/10.1101/2020.06.18.20135152>

778 132. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome.
779 Nature. 2018;558(7708):73-79. doi:10.1038/s41586-018-0175-2

780 133. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity
781 of COVID-19. J Med Virol. 2020;92(11):2409-2411. doi:10.1002/jmv.26097

782 134. Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32(4):274-278.
783 doi:10.3109/07853890009011772

- 784 135. Sheu WH, Wang WC, Wu KD, et al. CRP-level-associated polymorphism rs1205 within the
785 CRP gene is associated with 2-hour glucose level: The SAPPHiRe study. *Sci Rep.* 2017;7(1):7987.
786 Published 2017 Aug 11. doi:10.1038/s41598-017-08696-2
- 787 136. Chou SC, Ko HW, Lin YC. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate
788 with the Susceptibility and Severity of Community-Acquired Pneumonia [published correction
789 appears in *Genet Test Mol Biomarkers.* 2019 Jun;23(6):433]. *Genet Test Mol Biomarkers.*
790 2016;20(12):732-740. doi:10.1089/gtmb.2016.0156
- 791 137. Chan KY, Ching JC, Xu MS, et al. Association of ICAM3 genetic variant with severe acute
792 respiratory syndrome. *J Infect Dis.* 2007;196(2):271-280. doi:10.1086/518892
- 793 138. Meyer NJ, Feng R, Li M, et al. IL1RN coding variant is associated with lower risk of acute
794 respiratory distress syndrome and increased plasma IL-1 receptor antagonist. *Am J Respir Crit Care*
795 *Med.* 2013;187(9):950-959. doi:10.1164/rccm.201208-1501OC
- 796 139. Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS
797 onset? What is there besides Tocilizumab? *SGP130Fc. Cytokine X.* 2020;2(2):100029.
798 doi:10.1016/j.cytex.2020.100029
- 799 140. Nakanishi T, Pigazzini S, Degenhardt F, et al. Age-dependent impact of the major common
800 genetic risk factor for COVID-19 on severity and mortality. Preprint. medRxiv.
801 2021;2021.03.07.21252875. Published 2021 Mar 12. doi:10.1101/2021.03.07.21252875
- 802 141. Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in
803 surviving patients. *The Egyptian Journal of Radiology and Nuclear Medicine.* 2021;52(1):101.
804 doi:10.1186/s43055-021-00484-3
- 805 142. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and
806 pulmonary fibrosis. *N Engl J Med.* 2011;364(16):1503-1512. doi:10.1056/NEJMoa1013660
- 807 143. Andolfo I, Russo R, Lasorsa VA, et al. Common variants at 21q22.3 locus influence MX1
808 and TMPRSS2 gene expression and susceptibility to severe COVID-19. *iScience.*
809 2021;24(4):102322. doi:10.1016/j.isci.2021.102322
- 810 144. Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of
811 COVID-19 related mortality from UK Biobank data. *Hum Genomics.* 2021;15(1):10. Published 2021
812 Feb 3. doi:10.1186/s40246-021-00306-7
- 813 145. Gómez J, Albaiceta GM, García-Clemente M, et al. Angiotensin-converting enzymes (ACE,
814 ACE2) gene variants and COVID-19 outcome. *Gene.* 2020;762:145102.
815 doi:10.1016/j.gene.2020.145102
- 816 146. Liu C, Pei J, Lai Y, et al. Association of ACE2 variant rs4646188 with the risks of atrial
817 fibrillation and cardioembolic stroke in Uygur patients with type 2 diabetes. *BMC Cardiovasc*
818 *Disord.* 2021;21(1):103. Published 2021 Feb 18. doi:10.1186/s12872-021-01915-9
- 819 147. Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to
820 essential hypertension and dyslipidemia in Xinjiang, China. *Lipids Health Dis.* 2018;17(1):241.
821 Published 2018 Oct 20. doi:10.1186/s12944-018-0890-6

148. Luo Y, Liu C, Guan T, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang [published correction appears in Hypertens Res. 2019 Jan 23;:]. Hypertens Res. 2019;42(5):681-689. doi:10.1038/s41440-018-0166-6
149. Kochetova OV, Avzaletdinova DS, Morugova TV, Mustafina OE. Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia. Mol Biol Rep. 2019;46(1):887-896. doi:10.1007/s11033-018-4544-6
150. polymorphism with tuberculosis susceptibility: A meta-analysis. Innate Immun. 2020;26(5):358-363. doi:10.1177/1753425919891662 rs2107538 Sheng YF, Qi Q. Association of chemotactic chemokine ligand 5
151. Lu S, Wang Y, Wang Y, et al. The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk. J Cell Mol Med. 2020;24(11):6191-6207. doi:10.1111/jcmm.15246
152. Oosterveer DM, Versmissen J, Defesche JC, et al. Low-density lipoprotein receptor mutations generate synthetic genome-wide associations. Eur J Hum Genet. 2013;21(5):563-566. doi:10.1038/ejhg.2012.207
153. <https://mapmygenome.in/>
154. <https://covid19.who.int/>
155. <https://ourworldindata.org/coronavirus>

853
854
855
856

Table 1: Genetic variants related to COVID-19 susceptibility.

^p Effect allele frequency in Indian population. ^q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

rsid	Gene	EA	OA	IND ^p (EAF)	AFR (EAF)	AMR (EAF)	EAS (EAF)	EUR (EAF)	SAS (EAF)	EAF comparison ^q	Effect	Ref
rs4343	ACE	A	G	0.604	0.805	0.607	0.68	0.435	0.627	EUR < IND = AMR = SAS < EAS < AFR	Increased susceptibility to COVID-19	53, 54
rs2285666	ACE2	A	G	0.459	0.207	0.326	0.536	0.239	0.487	AFR < EUR < AMR < IND = SAS < EAS	Increased levels of ACE2 in serum; increased susceptibility to COVID-19	48
rs4240157	ACE2	T	C	0.69	0.459	0.712	0.965	0.657	0.724	AFR < EUR < IND = AMR = SAS < EAS	Increased expression of ACE2; increased susceptibility to COVID-19	49, 41
rs4646188	ACE2	G	A	0.062	0.003	0.032	0	0.136	0.061	EAS < AFR < AMR = SAS = IND < EUR	Increased expression of ACE2; increased susceptibility to COVID-19	50, 51, 41
rs2158083	ACE2	T	C	0.76	0.828	0.755	0.995	0.664	0.812	EUR < AMR = IND < SAS < AFR < EAS	Increased expression of PIR and ACE2; increased susceptibility to COVID-19	41, 50
rs1978124	ACE2	C	T	0.724	0.902	0.71	0.995	0.544	0.792	EUR < AMR = IND < SAS < AFR < EAS	Increased expression of PIR and ACE2; increased susceptibility to COVID-19	41, 50
rs233574	ACE2	T	C	0.176	0.084	0.235	0.004	0.315	0.177	EAS < AFR < IND < SAS < AMR < EUR	Increased expression of ACE2; increased susceptibility to COVID-19	52
rs55790676	ADAM17	G	T	0.925	0.919	0.866	0.98	0.816	0.904	EUR < AMR < SAS = AFR = IND < EAS	Decreased ADAM17 expression; increased susceptibility to COVID-19	41, 50
rs1524668	ADAM17	A	C	0.597	0.297	0.569	0.906	0.338	0.573	AFR < EUR < AMR = SAS = IND < EAS	Decreased ADAM17 expression; increased susceptibility to COVID-19	50, 41
rs2248690	AHSG	T	A	0.17	0.278	0.365	0.161	0.244	0.177	EAS = IND = SAS < EUR < AFR < AMR	Decreased AHSG levels and increased SARS-COV susceptibility; increased susceptibility to COVID-19	94
rs1532423	CA1	G	A	0.494	0.862	0.565	0.468	0.629	0.459	SAS = EAS = IND < AMR < EUR < AFR	Decreased zinc levels; increased susceptibility to COVID-19	99
rs1996225	CA5BP1	T	C	0.541	0.607	0.586	0.782	0.48	0.622	EUR < IND < AMR < AFR < SAS < EAS	Increased expression of ACE2; increased susceptibility to COVID-19	41, 105
rs4060	CA5BP1	A	C	0.645	0.692	0.69	0.931	0.544	0.702	EUR < IND = AMR < AFR < SAS < EAS	Increased expression of ACE2; increased susceptibility to COVID-19	41, 105
rs7248637	CD209	C	T	0.948	0.624	0.903	0.685	0.885	0.83	AFR < EAS < SAS < EUR < AMR < IND	Increased susceptibility to COVID-19	106, 107
rs3128509	CTSL	A	G	0.191	0.126	0.408	0.018	0.413	0.204	EAS < AFR < IND = SAS < AMR < EUR	Increased CTSL expression in various tissues; increased susceptibility to COVID-19	41, 108
rs17823744	DMGDH	A	G	0.94	0.992	0.938	1	0.87	0.942	EUR < AMR = IND = SAS < AFR < EAS	Decreased selenium levels; decreased immune response; increased susceptibility to COVID-19	99
rs13015258	DPP4	T	G	0.315	0.318	0.602	0.621	0.4	0.327	IND = AFR = SAS < EUR < AMR < EAS	Increased DPP4 (CD26) expression in lungs; increased COVID-19 susceptibility	109, 110, 41

rs9340799	ESR1	G	A	0.377	0.265	0.272	0.193	0.308	0.373	EAS < AFR < AMR < EUR < SAS = IND	Potential alteration of expression of ESR-alpha, thereby affecting ACE2 expression	64
rs4702	FURIN	A	G	0.499	0.941	0.589	0.525	0.563	0.499	SAS = IND = EAS < EUR < AMR < AFR	Increased FURIN expression; increased susceptibility to COVID-19	65
rs4932178	FURIN	T	C	0.276	0.287	0.209	0.16	0.356	0.286	EAS < AMR < IND = SAS = AFR < EUR	Increased FURIN expression; increased susceptibility to COVID-19	64, 41
rs71076692	HNF1A	CT	C	0.313	0.592	0.48	0.487	0.456	0.369	IND < SAS < EUR < AMR < EAS < AFR	Increased plasma ACE2 concentration in males; increased susceptibility to COVID-19	111, 112
rs9666637	IFITM3	T	A	0.912	0.757	0.689	0.393	0.864	0.81	EAS < AMR < AFR < SAS < EUR < IND	Increased expression of IFITM2 in cultured fibroblast cells; increased susceptibility to COVID-19	114, 41, 113
rs11246066	IFITM3 - LOC105376504	A	C	0.189	0.026	0.29	0.554	0.258	0.219	AFR < IND = SAS < EUR < AMR < EAS	Increased IFITM3 expression in whole blood; increased susceptibility to COVID-19	114, 41, 113
rs7931303	IFITM3 - LOC105376504	G	A	0.398	0.077	0.526	0.558	0.676	0.422	AFR < IND = SAS < AMR < EAS < EUR	Increased IFITM1 and IFITM2 expression in whole blood; increased susceptibility to COVID-19	114, 41
rs2093932	KCNT2	C	T	0.933	0.998	0.991	0.998	0.969	0.944	IND = SAS < EUR < AMR < AFR < EAS	Increased susceptibility to COVID-19	115
rs35477708	MX1	GA	G	0.35	0.556	0.602	0.191	0.633	0.521	EAS < IND < SAS < AFR < AMR < EUR	Increased TMPRSS2 expression; increased susceptibility to COVID-19	41, 47
rs468259	MX1	C	G	0.485	0.36	0.334	0.249	0.54	0.485	EAS < AMR < AFR < SAS = IND < EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs363981	MX1	T	G	0.261	0.104	0.29	0.01	0.484	0.249	EAS < AFR < SAS = IND = AMR < EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs1638369	MX1	T	G	0.341	0.382	0.448	0.106	0.573	0.364	EAS < IND = SAS = AFR < AMR < EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs469288	MX1	G	A	0.551	0.443	0.468	0.348	0.588	0.547	EAS < AFR < AMR < SAS = IND = EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs468699	MX1	C	T	0.347	0.468	0.336	0.101	0.539	0.366	EAS < AMR = IND = SAS < AFR < EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs462698	MX1	A	G	0.341	0.382	0.448	0.106	0.574	0.364	EAS < IND = SAS = AFR < AMR < EUR	Increased TMPRSS2 expression, increased susceptibility to COVID-19	41, 47
rs4826508	NBDY	C	T	0.273	0.372	0.408	0.364	0.272	0.294	EUR = IND = SAS < EAS < AFR < AMR	Decreased zinc levels, increased susceptibility to COVID-19	116, 99
rs1042838	PGR	A	C	0.078	0.006	0.137	0.01	0.179	0.066	AFR < EAS < SAS = IND < AMR < EUR	Affects PGR protein function, increased susceptibility to COVID-19	53, 74
rs2120019	PPCDC	C	T	0.62	0.486	0.246	0.611	0.208	0.595	EUR < AMR < AFR < SAS = EAS = IND	Decreased serum zinc levels, increased susceptibility to COVID-19	99
rs1893217	PTPN2	G	A	0.183	0.036	0.061	0.192	0.141	0.178	AFR < AMR < EUR < SAS = IND = EAS	Increased ACE2 expression, increased susceptibility to COVID-19	117, 41

rs35746115	SDK2	C	A	0.926	0.916	0.865	0.973	0.764	0.926	EUR < AMR < AFR = IND = SAS < EAS	Increased risk of COVID-19 susceptibility	115
rs12950851	SDK2	C	T	0.947	0.991	0.873	0.971	0.769	0.914	EUR < AMR < SAS < IND < EAS < AFR	Increased risk of COVID-19 susceptibility	115
rs461194	TMPRSS2	G	C	0.916	0.995	0.772	0.653	0.969	0.887	EAS < AMR < SAS < IND < EUR < AFR	Predicted to alter the splicing silencer motif of TMPRSS2 which is likely to affect TMPRSS2 structure and function	118
rs456016	TMPRSS2	T	C	0.056	0.02	0.231	0.349	0.019	0.075	EUR < AFR < IND = SAS < AMR < EAS	Predicted to modify and/or create splice enhancer site, donor site and silencer site thereby affecting TMPRSS2 splicing	118
rs467375	TMPRSS2	A	G	0.372	0.093	0.239	0.006	0.441	0.384	EAS < AFR < AMR < IND = SAS < EUR	Increased TMPRSS2 expression in lungs, increased susceptibility to COVID-19	41, 47
rs2094881	TMPRSS2	C	T	0.681	0.476	0.509	0.256	0.748	0.676	EAS < AFR < AMR < SAS = IND < EUR	Predicted to modify the splice enhancer site in TMPRSS2 gene, potentially affecting TMPRSS2 expression	118
rs4818239	TMPRSS2	C	T	0.425	0.25	0.336	0.008	0.502	0.446	EAS < AFR < AMR < IND = SAS < EUR	Increased TMPRSS2 expression in lungs, increased susceptibility to COVID-19	41, 47
rs35899679	TMPRSS2	A	C	0.374	0.107	0.288	0.007	0.463	0.384	EAS < AFR < AMR < IND = SAS < EUR	Increased TMPRSS2 expression in lungs, increased susceptibility to COVID-19	41, 47
rs12627374	TMPRSS2	C	T	0.884	0.995	0.996	0.85	0.998	0.863	EAS = SAS = IND < AFR < AMR < EUR	Binding site for hsa-miR-345 created, might be altering TMPRSS2 expression	108
rs8134378	TMPRSS2	G	A	0.949	0.821	0.951	0.999	0.885	0.922	AFR < EUR < SAS < IND = AMR < EAS	Increased TMPRSS2 expression, increased susceptibility to COVID-19	77, 64, 41
rs140092351	LOC101928923	GTT TCT CTA GTT TGG A	G	0.143	0.597	0.334	0.228	0.223	0.148	IND = SAS < EUR < EAS < AMR < AFR	Increased susceptibility to COVID-19	115
rs80066318	LOC105370282 - LOC105370283	G	A	0.214	0.382	0.03	0.168	0.032	0.303	AMR < EUR < EAS < IND < SAS < AFR	Increased susceptibility to COVID-19	115
rs56248709	LOC105374172 - LOC100419750	C	T	0.071	0.263	0.094	0.031	0.153	0.073	EAS < IND = SAS = AMR < EUR < AFR	Increased susceptibility to COVID-19	115
rs62436931	LOC105378093	C	T	0.16	0.122	0.174	0	0.278	0.142	EAS < AFR < SAS = IND = AMR < EUR	Increased susceptibility to COVID-19	115

857
858
859
860
861
862
863

864
865
866
867

Table 2: Genetic variants related to host immune response to SARS-CoV2 infection.

^p Effect allele frequency in Indian population. ^q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

rsid	Gene	EA	OA	IND ^p (EAF)	AFR (EAF)	AMR (EAF)	EAS (EAF)	EUR (EAF)	SAS (EAF)	EAF comparison ^q	Literature data	Ref
rs1719152	CCL4	A	T	0.121	0.049	0.118	0.276	0.249	0.228	AFR < AMR = IND < SAS < EUR < EAS	Increased CCL4 and CCL3 expression in lungs, might be causing impaired immune response	41, 119
rs3817655	CCL5	A	T	0.873	0.546	0.78	0.679	0.841	0.823	AFR < EAS < AMR < SAS < EUR = IND	Increased CCL5 expression in whole blood, might be causing impaired immune response	41, 83, 42
rs2107538	CCL5	T	C	0.281	0.451	0.225	0.322	0.161	0.309	EUR < AMR < IND = SAS = EAS < AFR	Decreased CCL5 levels in whole blood, might be causing impaired immune response	41, 105
rs1015164	CCRL2 - LINC02009	G	A	0.753	0.953	0.777	0.813	0.683	0.717	EUR < SAS = IND = AMR < EAS < AFR	Increased CCR1 expression in whole blood, might be causing impaired immune response	41, 90
rs2306630	HEATR9	A	G	0.099	0.191	0.199	0.308	0.111	0.108	IND = SAS = EUR < AFR < AMR < EAS	Decreased HEATR9 and CCL5 expression in whole blood, might be causing impaired immune response	41, 120
rs4611572	ICAM3 - TYK2	G	C	0.575	0.38	0.486	0.658	0.579	0.547	AFR < AMR < SAS = IND = EUR < EAS	Decreased ICAM3 expression, might be causing impaired immune response	121, 41, 42, 122
rs1990760	IFIH1	T	C	0.516	0.126	0.39	0.187	0.605	0.564	AFR < EAS < AMR < IND < SAS < EUR	Protects against viral infection	79, 123
rs2430561	IFNG	A	T	0.364	0.167	0.254	0.159	0.462	0.39	EAS < AFR < AMR < IND = SAS < EUR	Increased SARS susceptibility	124
rs1024611	LINC01989 - CCL2	G	A	0.316	0.228	0.486	0.547	0.316	0.321	AFR < EUR = IND = SAS < AMR < EAS	Increased CCL2 expression, might be causing impaired immune response	91
rs1994182	MMP28	G	C	0.341	0.651	0.295	0.572	0.167	0.38	EUR < AMR = IND = SAS < EAS < AFR	Decreased CCL5 levels in whole blood, might be causing impaired immune response	41, 42, 89
rs3826404	MMP28	G	T	0.272	0.362	0.213	0.315	0.165	0.31	EUR < AMR < IND = SAS = EAS < AFR	Decreased CCL5 expression in whole blood, might be causing impaired immune response	41, 42, 89
rs1801133	MTHFR	A	G	0.165	0.09	0.474	0.296	0.365	0.119	AFR < SAS < IND < EAS < EUR < AMR	Decreased serum folate levels, might be causing impaired immune response	125, 126, 99
rs13303010	NOC2L	G	A	0.142	0.837	0.303	0.292	0.098	0.125	EUR < SAS = IND < EAS < AMR < AFR	Increased PLEKHN1 expression in CD4 T-cells (T cell, CD4, TFH)	127
rs2526327	RDM1	A	G	0.273	0.444	0.202	0.21	0.145	0.293	EUR < AMR < EAS < IND = SAS < AFR	Decreased CCL5 expression in whole blood, might be causing impaired immune response	41, 42
rs2769264	SELENBP1	T	G	0.792	0.703	0.588	0.714	0.839	0.785	AMR < AFR < EAS < SAS = IND < EUR	Decreased levels of copper in serum, might be causing impaired immune response	116
rs1175550	SMIM1	A	G	0.842	0.399	0.846	0.998	0.781	0.857	AFR < EUR < IND = AMR = SAS < EAS	Decreased levels of copper in serum, might be causing impaired immune response	99, 41

rs4239252	TAF15	A	G	0.32	0.607	0.288	0.456	0.162	0.366	EUR < AMR = IND = SAS < EAS < AFR	Increased expression of CCL5 in whole blood	41, 42
rs1061622	TNFRSF1B	G	T	0.249	0.187	0.127	0.15	0.218	0.276	AMR < EAS < AFR < EUR = IND = SAS	Increased TNFRSF1B expression in whole blood	41, 119

Table 3: Genetic variants related to COVID-19 severity.

^p Effect allele frequency in Indian population. ^q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

rsid	Gene	EA	OA	IND ^p (EAF)	AFR (EAF)	AMR (EAF)	EAS (EAF)	EUR (EAF)	SAS (EAF)	EAF comparison ^q	Effect	Ref
rs2519093	ABO	T	C	0.128	0.087	0.121	0.19	0.185	0.134	AFR < AMR = IND = SAS < EUR < EAS	Increased risk of COVID-19 severity	96, 128, 129
rs2074192	ACE2	T	C	0.222	0.351	0.405	0.43	0.432	0.227	IND < SAS < AFR < AMR < EAS < EUR	Increased risk of COVID-19 severity	130
rs4240157	ACE2	T	C	0.69	0.459	0.712	0.965	0.657	0.724	AFR < EUR < IND = AMR = SAS < EAS	Increased hospitalization due to COVID-19, increased risk of COVID-19 severity	131
rs13282163	ADAM9	A	C	0.94	0.995	0.944	0.915	0.912	0.839	SAS < EUR < EAS < IND = AMR < AFR	Increased risk of COVID-19 severity	86
rs12692386	ADAM17	G	A	0.509	0.983	0.484	0.219	0.669	0.531	EAS < AMR = IND = SAS < EUR < AFR	Increased ADAM17 expression in severe sepsis, increased risk of COVID-19 severity	50, 41
rs2765013	AGO1	C	T	0.881	0.477	0.61	0.364	0.913	0.864	EAS < AFR < AMR < SAS < IND = EUR	Increased risk of COVID-19 severity	86
rs1892429	ANKRD30A	A	G	0.907	0.992	0.759	0.917	0.757	0.912	EUR < AMR < IND = SAS = EAS < AFR	Increased risk of COVID-19 severity	86
rs10039856	ARHGAP26	C	T	0.813	0.555	0.847	0.324	0.915	0.794	EAS < AFR < SAS = IND = AMR < EUR	Increased risk of COVID-19 severity	86
rs7787942	C1GALT1	T	A	0.297	0.828	0.46	0.699	0.466	0.293	SAS = IND < AMR < EUR < EAS < AFR	Increased C1GALT1C1 protein levels in blood serum, and associated with COVID-19 severity	132, 96
rs1205	CRP	C	T	0.692	0.83	0.625	0.434	0.69	0.667	EAS < AMR < SAS = EUR = IND < AFR	Increased serum CRP levels, one of the major hallmarks of severe COVID-19, associated with susceptibility and severity of community acquired pneumonia	133, 134, 135, 136
rs3774882	EVC	C	G	0.848	0.687	0.937	0.9	0.93	0.781	AFR < SAS < IND < EAS < EUR < AMR	Increased risk of COVID-19 severity	86
rs3774881	EVC	T	C	0.786	0.193	0.64	0.751	0.857	0.745	AFR < AMR < SAS = EAS = IND < EUR	Increased risk of COVID-19 severity	86
rs17514846	FURIN	A	C	0.371	0.883	0.295	0.159	0.461	0.39	EAS < AMR < IND = SAS < EUR < AFR	Increased FURIN expression in vascular endothelial cells, increased risk of COVID-19 severity	62, 64
rs1155563	GC	C	T	0.296	0.057	0.186	0.336	0.244	0.316	AFR < AMR < EUR < IND = SAS = EAS	Decreased serum vitamin-D levels, increased risk of COVID-19 severity	99

rs3895472	GLIS3 - RNU6-694P	C	T	0.896	0.796	0.915	0.992	0.936	0.889	AFR < SAS = IND = AMR < EUR < EAS	Increased risk of COVID-19 severity	86
rs1799945	HFE	C	G	0.912	0.989	0.885	0.971	0.828	0.929	EUR < AMR = IND = SAS < EAS < AFR	Decreased iron bioavailability, increased risk of COVID-19 severity	99
rs10755709	HIVEP1	A	G	0.176	0.634	0.69	0.591	0.7	0.572	IND < SAS < EAS < AFR < AMR < EUR	Increased risk of COVID-19 severity	86
rs9380142	HLA-G	A	G	0.84	0.809	0.719	0.651	0.656	0.85	EAS < EUR < AMR < AFR < IND = SAS	Increased risk of COVID-19 severity	95
rs2304237	ICAM3	C	T	0.261	0.141	0.174	0.113	0.234	0.248	EAS < AFR < AMR < EUR = SAS = IND	Increased risk of COVID-19 severity	137
rs2236757	IFNAR2	A	G	0.425	0.193	0.428	0.565	0.294	0.468	AFR < EUR < IND = AMR = SAS < EAS	Increased risk of COVID-19 severity	95
rs13050728	IFNAR2	T	C	0.487	0.194	0.451	0.576	0.333	0.519	AFR < EUR < AMR = IND = SAS < EAS	Increased risk of COVID-19 severity	95
rs2270360	IGFBP2	A	C	0.927	0.976	0.659	0.585	0.695	0.776	EAS < AMR < EUR < SAS < IND < AFR	Increased risk of COVID-19 severity	86
rs1800872	IL10	T	G	0.435	0.436	0.333	0.676	0.24	0.458	EUR < AMR < IND = AFR = SAS < EAS	Increased risk of COVID-19 severity	136, 105, 41
rs315952	IL1RN	T	C	0.887	0.534	0.785	0.444	0.72	0.851	EAS < AFR < EUR < AMR < SAS < IND	Increased risk of developing acute respiratory distress syndrome (ARDS)	138
rs1800797	IL6	A	G	0.17	0.017	0.184	0.001	0.408	0.134	EAS < AFR < SAS = IND = AMR < EUR	Increased risk of severe community acquired pneumonia and increased IL6 expression in cultured fibroblast cells, might be associated with increased COVID-19 severity	139, 136, 41
rs10766439	KCNQ1DN - CDKN1C	A	G	0.351	0.241	0.199	0.008	0.365	0.374	EAS < AMR < AFR < IND = EUR = SAS	Increased risk of COVID-19 severity	86
rs1870377	KDR - VEGFR2	A	T	0.173	0.09	0.131	0.465	0.235	0.149	AFR < AMR = SAS = IND < EUR < EAS	Decreased stability of VEGFR2, contributing to COVID-19 progression or pathogenesis	119
rs4240376	LINC01170 - ZNF608	G	T	0.69	0.887	0.713	0.578	0.789	0.704	EAS < IND = SAS = AMR < EUR < AFR	Increased risk of COVID-19 severity	86
rs1800630	LTA - TNF	A	C	0.283	0.1	0.134	0.164	0.145	0.241	AFR < AMR < EUR < EAS < SAS = IND	Increased risk of developing acute respiratory distress syndrome (ARDS), increased risk of COVID-19 severity	93
rs10490770	LZTFL1	C	T	0.251	0.004	0.043	0.005	0.081	0.296	AFR < EAS < AMR < EUR < IND = SAS	Increased risk of COVID-19 severity, COVID-19 related severe respiratory failure, COVID-19 related Venous thromboembolism and COVID-19 related hepatic injury	140
rs113791144	MGAT1	T	C	0.194	0.043	0.143	0.036	0.083	0.168	EAS < AFR < EUR < AMR < SAS = IND	Increased risk of COVID-19 severity	86
rs35619543	MUC5B	T	G	0.085	0.362	0.245	0.033	0.26	0.195	EAS < IND < SAS < AMR < EUR < AFR	Increased risk of pulmonary fibrosis, increased risk of COVID-19 severity	141, 142, 113
rs35477708	MX1	G	GA	0.65	0.444	0.398	0.809	0.367	0.479	EUR < AMR < AFR < SAS < IND < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47

rs468259	MX1	G	C	0.515	0.64	0.666	0.751	0.46	0.515	EUR < IND = SAS < AFR < AMR < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47
rs363981	MX1	G	T	0.739	0.896	0.71	0.99	0.516	0.751	EUR < AMR = IND = SAS < AFR < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47
rs1638369	MX1	G	T	0.659	0.618	0.552	0.894	0.427	0.636	EUR < AMR < AFR = SAS = IND < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47
rs469288	MX1	A	G	0.449	0.557	0.532	0.652	0.412	0.453	EUR = IND = SAS < AMR < AFR < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47
rs468699	MX1	T	C	0.653	0.532	0.664	0.899	0.461	0.634	EUR < AFR < SAS = IND = AMR < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41, 47
rs462698	MX1	G	A	0.659	0.618	0.552	0.894	0.426	0.636	EUR < AMR < AFR = SAS = IND < EAS	Decreased MX1 expression, increased risk of COVID-19 severity	41
rs10735079	OAS1-OAS3	A	G	0.698	0.812	0.756	0.748	0.636	0.717	EUR < IND = SAS < EAS < AMR < AFR	Increased risk of COVID-19 severity	95
rs10808999	PLEKHA2	G	A	0.861	0.977	0.925	0.921	0.859	0.883	EUR = IND = SAS < EAS < AMR < AFR	Increased risk of COVID-19 severity	86
rs6065904	PLTP	A	G	0.325	0.212	0.38	0.337	0.244	0.35	AFR < EUR < IND = EAS = SAS < AMR	Increased risk of COVID-19 severity	96, 132
rs2010843	RDH10-AS1	C	T	0.539	0.066	0.659	0.628	0.556	0.538	AFR < SAS = IND = EUR < EAS < AMR	Increased risk of COVID-19 severity	86
rs2238187	RGS6	G	A	0.308	0.185	0.29	0.624	0.389	0.3	AFR < AMR = SAS = IND < EUR < EAS	Increased risk of COVID-19 severity	86
rs12083278	RPL21P22 - LOC107984935	C	G	0.941	0.83	0.637	0.721	0.642	0.843	AMR < EUR < EAS < AFR < SAS < IND	Increased risk of COVID-19 severity	86
rs2229117	RYR3	G	C	0.913	0.969	0.824	0.963	0.867	0.918	AMR < EUR < IND = SAS < EAS < AFR	Increased risk of COVID-19 severity	86
rs12593288	RYR3	C	T	0.805	0.976	0.738	0.486	0.811	0.71	EAS < SAS < AMR < IND = EUR < AFR	Increased risk of COVID-19 severity	86
rs34761447	STX8	C	T	0.851	0.992	0.951	0.815	0.905	0.788	SAS < EAS = IND < EUR < AMR < AFR	Increased risk of COVID-19 severity	86
rs2220543	SUMO2P6 - LOC105377740	T	A	0.548	0.585	0.633	0.491	0.704	0.512	EAS < SAS = IND = AFR < AMR < EUR	Increased risk of COVID-19 severity	86
rs2274122	TEKT2	A	G	0.662	0.191	0.519	0.27	0.82	0.613	AFR < EAS < AMR < SAS < IND < EUR	Increased risk of COVID-19 severity	86
rs12329760	TMPRSS2	T	C	0.243	0.287	0.154	0.362	0.236	0.226	AMR < SAS = EUR = IND < AFR < EAS	Increased risk of COVID-19 severity	143
rs2094881	TMPRSS2	C	T	0.681	0.476	0.509	0.256	0.748	0.676	EAS < AFR < AMR < SAS = IND < EUR	Increased risk of COVID-19 severity	118, 143
rs60744406	ZNF155	G	A	0.505	0.18	0.376	0.257	0.571	0.492	AFR < EAS < AMR < SAS < IND < EUR	Increased risk of COVID-19 severity	86

rs71481792	LINC02676 - LOC101928272	A	T	0.615	0.762	0.51	0.65	0.35	0.626	EUR < AMR < IND = SAS = EAS < AFR	Increased risk of COVID-19 severity	86
rs1984162	LOC105370111 - LOC105370112	G	A	0.173	0.222	0.187	0.083	0.269	0.176	EAS < IND = SAS = AMR < AFR < EUR	Increased risk of COVID-19 severity	86
rs9386484	LOC105377923	T	A	0.789	0.616	0.548	0.637	0.72	0.615	AMR < SAS < AFR < EAS < EUR < IND	Increased risk of COVID-19 severity	86
rs7027911	LOC107987083 - MTCO1P50	A	G	0.535	0.887	0.569	0.662	0.417	0.517	EUR < SAS = IND = AMR < EAS < AFR	Increased risk of COVID-19 severity	86
rs12133284	LOC112268258	T	A	0.148	0.34	0.14	0.013	0.233	0.148	EAS < AMR = IND = SAS < EUR < AFR	Increased risk of COVID-19 severity	115

Table 4: Genetic variants related to COVID-19 related fatal outcomes or mortality.

^p Effect allele frequency in Indian population. ^q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele, Ref – references).

rsid	Gene	EA	OA	IND ^p (EAF)	AFR (EAF)	AMR (EAF)	EAS (EAF)	EUR (EAF)	SAS (EAF)	EAF comparison ^q	Effect	Ref
rs2074192	ACE2	T	C	0.222	0.351	0.405	0.43	0.432	0.227	IND < SAS < AFR < AMR < EAS < EUR	Increased risk of COVID-19 related mortality	71
rs2874140	CPQ	T	A	0.336	0.419	0.287	0.627	0.21	0.328	EUR < AMR = SAS = IND < AFR < EAS	Increased risk of COVID-19 related mortality	102
rs71040457	DES - SPEG	A	AG	0.276	0.939	0.385	0.177	0.376	0.293	EAS < IND = SAS < EUR < AMR < AFR	Increased risk of COVID-19 related mortality	102
rs6598045	IFITM3	A	G	0.841	0.701	0.778	0.859	0.894	0.723	AFR < SAS < AMR < IND < EAS < EUR	Increased risk of COVID-19 related mortality	71
rs73060484	LOC105376755	C	A	0.065	0.115	0.236	0.235	0.077	0.134	IND = EUR < AFR < SAS < EAS < AMR	Increased risk of COVID-19 related mortality	144
rs10490770	LZTFL1	C	T	0.251	0.004	0.043	0.005	0.081	0.296	AFR < EAS < AMR < EUR < IND = SAS	Increased risk of COVID-19 related mortality	140
rs55986907	RPS26P32 - TOMM7	T	C	0.373	0.123	0.337	0.159	0.284	0.374	AFR < EAS < EUR < AMR = IND = SAS	Increased risk of COVID-19 related mortality	102
rs113892140	SLC39A10	A	G	0.078	0.256	0.238	0.202	0.046	0.077	EUR < SAS = IND < EAS < AMR < AFR	Increased risk of COVID-19 related mortality	102
rs2298659	TMPRSS2	G	A	0.834	0.825	0.782	0.751	0.77	0.811	EAS < EUR < AMR < SAS = AFR = IND	Increased risk of COVID-19 related mortality	71

882 **Table 5: Genetic variants related to comorbidities that are risk factors of COVID-19 susceptibility/severity.**
883 ^p Effect allele frequency in Indian population. ^q EAF (India) compared with EAF in other populations (IND – India, EUR – Europe, AMR – America, SAS – South
884 Asia, AFR – Africa, EAS – East Asia. ‘=’ denotes no significant difference between EAF of Indian and the other population. (EA – effect allele, OA – other allele,
885 Ref – references).

rsid	Gene	EA	OA	IND ^p (EAF)	AFR (EAF)	AMR (EAF)	EAS (EAF)	EUR (EAF)	SAS (EAF)	EAF comparison ^q	Effect	Ref
rs2285666	ACE2	A	G	0.459	0.207	0.326	0.536	0.239	0.487	AFR < EUR < AMR < IND = SAS < EAS	Increased risk of developing hypertension, which might increase the risk for COVID-19 severity	145
rs4240157	ACE2	C	T	0.31	0.541	0.288	0.035	0.343	0.276	EAS < SAS = AMR = IND < EUR < AFR	Increased risk of developing hypertension and Type 2 diabetes, which might increase the risk for COVID-19 severity	50, 49
rs4646188	ACE2	A	G	0.938	0.997	0.968	1	0.864	0.939	EUR < IND = SAS = AMR < AFR < EAS	Increased risk of developing hypertension, which might alter COVID-19 severity Increased risk of developing atrial fibrillation and cardioembolic stroke in diabetic patients	50, 146
rs2158083	ACE2	C	T	0.24	0.172	0.245	0.005	0.336	0.188	EAS < AFR < SAS < IND = AMR < EUR	Associated with changes in blood pressure, potentially affecting COVID-19 susceptibility and severity	50
rs1978124	ACE2	T	C	0.276	0.098	0.29	0.005	0.456	0.208	EAS < AFR < SAS < IND = AMR < EUR	Increased risk of developing hypertension, which might increase the risk for COVID-19 severity	50, 130
rs2074192	ACE2	T	C	0.222	0.351	0.405	0.43	0.432	0.227	IND < SAS < AFR < AMR < EAS < EUR	Increased risk of developing hypertension, potentially affecting COVID-19 susceptibility and severity	49
rs4646155	ACE2	T	C	0.069	0.136	0.019	0.032	0.002	0.085	EUR < AMR < EAS < IND = SAS < AFR	Increased risk of developing essential hypertension, thereby modulating COVID-19 susceptibility and severity,	147
rs2106809	ACE2	T	C	0.545	0.913	0.687	0.477	0.751	0.509	EAS < SAS = IND < AMR < EUR < AFR	Increased risk of developing essential hypertension, thereby modulating COVID-19 susceptibility and severity,	148
rs55790676	ADAM17	T	G	0.075	0.081	0.134	0.02	0.184	0.096	EAS < IND = AFR = SAS < AMR < EUR	Decreased total cholesterol levels and increased HDL levels, potentially affecting COVID-19 severity	50
rs2107538	CCL5	T	C	0.281	0.451	0.225	0.322	0.161	0.309	EUR < AMR < IND = SAS = EAS < AFR	Associated with type 2 diabetes and tuberculosis, which might affect COVID-19 susceptibility and severity	149, 150
rs1800796	IL6	C	G	0.348	0.103	0.295	0.791	0.048	0.395	EUR < AFR < AMR = IND = SAS < EAS	Increased risk of coronary artery disease, which might affect COVID-19 severity	151
rs3745264	RAVER1	A	C	0.201	0.057	0.297	0.178	0.157	0.213	AFR < EUR < EAS = IND = SAS < AMR	Increased risk of developing familial hypercholesterolemia	152, 42